X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Fresenius Kabi Onco. Fact Sheet, Fresenius Kabi Onco. Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Fresenius Kabi Onco. Fact Sheet   (DBPH)

Here is the latest financial fact sheet of Fresenius Kabi Onco.. For more details, see the Fresenius Kabi Onco. quarterly results and Fresenius Kabi Onco. share price and chart. For a sector overview, read our pharmaceuticals sector report.

FRESENIUS KABI ONCO. Price History

Price Rs 132.5
Mkt Cap Rs m 20,958
Vol '000 91.5
P/E X 22.1
P/CF X 19.7
EPS (TTM) Rs 6.0
% ch % 0.3
No. of shares m 158.23
% ch week % 0.4
% ch 1-mth % 1.9
% ch 12-mth % 20.1
52 week H/L Rs 161.4/93.1
(As on Jan 2, 2014 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

FRESENIUS KABI ONCO. Financials

No. of Mths
Year Ending
12
Mar-09
*
12
Mar-10
*
12
Mar-11
12
Mar-12
12
Mar-13
5-Yr Chart
Click to enlarge
FRESENIUS KABI ONCO. EQUITY SHARE DATA
High Rs81163194165176 
Low Rs2935828279 
Sales per share (Unadj.) Rs19.730.226.133.337.7 
Earnings per share (Unadj.) Rs-9.2-2.13.13.25.1 
Diluted earnings per shareRs-9.2-2.13.13.25.1 
Cash flow per share (Unadj.) Rs-7.4-0.14.24.76.7 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs17.815.734.237.542.5 
Adj. book value per shareRs17.815.734.237.542.5 
Shares outstanding (eoy) m158.23158.23158.23158.23158.23 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x2.83.35.33.73.4 
Avg P/E ratio x-6.0-47.044.338.425.0 
P/CF ratio (eoy) x-7.4-1,103.233.026.118.9 
Price / Book Value ratio x3.16.34.03.33.0 
Dividend payout %00000 
Avg Mkt Cap Rs m8,70315,66521,83619,54120,135 
No. of employees `0000.80.91.11.11.2 
Total wages/salary Rs m1,008695561610703 
Avg. sales/employee Rs Th3,789.65,088.43,649.64,784.55,176.2 
Avg. wages/employee Rs Th1,222.9738.9496.1553.9610.4 
Avg. net profit/employee Rs Th-1,772.0-354.9435.4462.7699.6 
FRESENIUS KABI ONCO. INCOME DATA
Net Sales Rs m3,1234,7834,1285,2685,963 
Other income Rs m223140592918 
Total revenues Rs m3,3464,9234,1875,2975,981 
Gross profit Rs m-1,2342277376591,430 
Depreciation Rs m282319169240258 
Interest Rs m291322-47177-26 
Profit before tax Rs m-1,585-2756732721,216 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m153027445-68 
Tax Rs m2859208208342 
Profit after tax Rs m-1,460-334492509806 
Gross profit margin %-39.54.717.812.524.0 
Effective tax rate %-1.8-21.430.876.328.1 
Net profit margin %-46.8-7.011.99.713.5 
FRESENIUS KABI ONCO. BALANCE SHEET DATA
Current assets Rs m3,5635,4205,4524,6795,102 
Current liabilities Rs m3,5444,5963,8382,0902,385 
Net working cap to sales %0.617.239.149.245.6 
Current ratio x1.01.21.42.22.1 
Inventory Days Days166187183129150 
Debtors Days Days11798156140113 
Net fixed assets Rs m4,8975,2803,5394,4535,148 
Share capital Rs m158158158158158 
"Free" reserves Rs m2,6422,3092,4695,7506,556 
Net worth Rs m2,8112,4825,4135,9266,732 
Long term debt Rs m2,0163,602952952952 
Total assets Rs m8,53710,78410,5929,21310,388 
Interest coverage x-4.40.1-13.42.5-45.8 
Debt to equity ratio x0.71.50.20.20.1 
Sales to assets ratio x0.40.40.40.60.6 
Return on assets %-13.7-0.14.27.47.5 
Return on equity %-51.9-13.49.18.612.0 
Return on capital %-23.60.810.313.014.6 
Exports to sales %59.174.280.877.274.5 
Imports to sales %16.315.819.318.724.8 
Exports (fob) Rs m1,8463,5513,3354,0694,441 
Imports (cif) Rs m5087547969861,477 
Fx inflow Rs m1,9573,6103,3614,0725,298 
Fx outflow Rs m9089559911,2501,772 
Net fx Rs m1,0492,6542,3702,8223,525 
FRESENIUS KABI ONCO. CASH FLOW
From Operations Rs m -1,867 -724 500 1,743 1,274 
From Investments Rs m 535 -661 -1,157 168 -1,204 
From Financial Activity Rs m 1,409 1,504 492 -1,965 -196 
Net Cashflow Rs m 77 120 -165 -54 -126 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 81.0%
Indian inst/Mut Fund 0.3%
FIIs 9.6%
ADR/GDR 0.0%
Free float 9.1%
Shareholders 42,599
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B-310, Som Datt Chambers - 1, Bhikaji Cama Place, New Delhi -110 066
E-MAIL complianceofficer.india@fresenius-kabi.com WEB www.fresenius-kabi-oncology.com
TELEPHONE (011) 2610 5570 FAX (011) 2619 5965
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT MCS Limited, F-65, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-20
AUDITOR G. Basu & Co.
CHM: Rakesh Bhargava COMP SEC: Nikhil Kulshreshtha YEAR OF INC: 2004 BSE CODE: 532545 FV (Rs): 1 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ASTRAZENECA PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS